Combination radiofrequency thermal ablation and adjuvant IV liposomal doxorubicin increases tissue coagulation and intratumoural drug accumulation

International Journal of Hyperthermia

Volumn 20, Issue 7, 2004, Pages 781-802

  Ahmed, M ^a   Goldberg, S N ^a  

^a HARVARD MEDICAL SCHOOL   (United States)

Author keywords

Hyperthermia; Liposomal doxorubicin; Minimally invasive therapy; Radiofrequency; Tumour ablation

Indexed keywords

DOXORUBICIN; LIPOSOME;

ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER ADJUVANT THERAPY; CANCER CHEMOTHERAPY; CANCER CONTROL; CANCER SURVIVAL; COMPARATIVE STUDY; CYTOTOXICITY; DRUG ACCUMULATION; DRUG DELIVERY SYSTEM; HYPERTHERMIC THERAPY; LIPID PEROXIDATION; LIVER TUMOR; NONHUMAN; NONSURGICAL INVASIVE THERAPY; RADIOFREQUENCY; TUMOR GROWTH;

ANTIBIOTICS, ANTINEOPLASTIC; CATHETER ABLATION; CHEMOTHERAPY, ADJUVANT; DOXORUBICIN; HUMANS; HYPERTHERMIA, INDUCED; INJECTIONS, INTRAVENOUS; LIPOSOMES; NEOPLASMS; TREATMENT OUTCOME;

EID: 8644276416     PISSN: 02656736     EISSN: None     Source Type: Journal    
DOI: 10.1080/02656730410001711655     Document Type: Article

References (97)

1. Dupuy D, Goldberg S. Image-guided radiofrequency tumor ablation: challenges and opportunities - part II. JVIR 2001;12: 1135-48.
2. Dodd GD, 3rd, Soulen MC, Kane RA, Livraghi T, Lees WN, Yamashita Y, Gillams AR, Karahan OI, Rhim H. Minimally invasive treatment of malignant hepatic tumors: at the threshold of a major breakthrough. Radiographics 2000; 20: 9-27.
3. McGahan JP, Dodd GD, 3rd. Radiofrequency ablation of the liver: current status. AJR Am J Roentgenol 2001; 176: 3-16.
4. Goldberg SN, Dupuy DE. Image-guided radiofrequency tumor ablation: challenges and opportunities - Part I. JVIR 2001; 12: 1021-32.
5. Goldberg SN, Gazelle GS, Mueller PR. Thermal ablation therapy for focal malignancy: a unified approach to underlying principles, technqiues, and diagnostic imaging guidance. Am J Radiol 2000; 174: 323-31.
6. Ahmed M, Goldberg SN. Thermal ablation therapy for hepatocellular carcinoma. J Vasc Interv Radiol 2002; 13: S231-44.
7. Goldberg SN, Ahmed M. Minimally invasive image-guided therapies for hepatocellular carcinoma. J Clin Gastroenterol 2002; 35: S115-29.
8. Gazelle GS, Goldberg SN, Solbiati L, Livraghi T. Tumor ablation with radiofrequency energy. Radiology 2000; 217: 6333-46.
9. Rhim H, Dodd GD, 3rd. Radiofrequency thermal ablation of liver tumors. J Clin Ultrasound 1999; 27: 221-9.
10. Solbiati L, Livraghi T, Goldberg SN, Ierace T, DellaNoce M, Gazelle GS. Percutaneous radiofrequency ablation of hepatic metastases from colorectal cancer: long term results in 117 patients. Radiology 2001; 221: 159-66.
11. Livraghi T, Solbiati L, Meloni MF, Gazelle GS, Halpern EF, Goldberg SN. Treatment of focal liver tumors with percutaneous radio-frequency ablation: complications encountered in a multicenter study. Radiology 2003; 226: 441-51.
12. Curley SA, Izzo F, Ellis LM, Nicolas Vauthey J, Vallone P. Radiofrequency ablation of hepatocellular cancer in 110 patients with cirrhosis. Ann Surg 2000; 232: 381-91.
13. Livraghi T, Meloni F, Goldberg SN, Lazzaroni S, Solbiati L, Gazelle GS. Hepatocellular carcinoma: radiofrequency ablation of medium and large lesions. Radiology 2000; 214: 761-8.
14. Wood TF, Rose DM, Chung M, Allegra DP, Foshag LJ, Bilchik AJ. Radiofrequency ablation of 231 unresectable hepatic tumors: indications, limitations, and complications. Ann Surg Oncol 2000; 7: 593-600.
15. de Baere T, Elias D, Dromain C, Din MG, Kuoch V, Ducreux M, Boige V, Lassau N, Marteau V, Lasser P, Roche A. Radiofrequency ablation of 100 hepatic metastases with a mean follow-up of more than 1 year. AJR Am J Roentgenol 2000; 175: 1619-25.
16. Yoshida Y, Kanematsu T, Matsumata T, Takenaka K, Sugimachi K. Surgical margin and recurrence after resection of hepatocellular carcinoma in patients with cirrhosis. Further evaluation of limited hepatic resection. Ann Surg 1989; 209: 297-301.
17. Friedman S, McQuaid K, Grendell J. Chapter 26: Malignant and premalignant lesions of the colon. Current Diagnosis and Treatment in Gastroenterology, 2nd edn. Lange Medical Books/McGraw-Hill, 2003; 569-576.
18. Dodd GD, 3rd, Frank MS, Aribandi M, Chopra S, Chintapalli KN. Radiofrequency thermal ablation: computer analysis of the size of the thermal injury created by overlapping ablations. AJR Am J Roentgenol 2001; 177: 777-82.
19. Goldberg SN, Stein M, Gazelle GS, Sheiman RG, Kruskal JB, Clouse ME. Percutaneous radiofrequency tissue ablation: optimization of pulsed-RF technique to increase coagulation necrosis. JVIR 1999; 10: 907-16.
20. Goldberg SN, Hahn PF, Halpern EF, Fogle R, Gazelle GS. Radiofrequency tissue ablation: effect of pharmacologic modulation of blood flow on coagulation diameter. Radiology 1998; 209: 761-9.
21. Goldberg SN, Gazelle GS, Dawson SL, Mueller PR, Rittman WJ, Rosenthal DI. Radiofrequency tissue ablation using multiprobe arrays: Greater tissue destruction than multiple probes operating alone. Acad Radiol 1995; 2: 670-4.
22. Goldberg SN, Solbiati L, Hahn PF, Cosman E, Conrad JE, Fogle R, Gazelle GS. Large-volume tissue ablation with radiofrequency by using a clustered, internally-cooled electrode technique: laboratory and clinical experience in liver metastases. Radiology 1998; 209: 371-9.
23. Goldberg SN, Gazelle GS, Solbiati L, Rittman WJ, Mueller PR. Radiofrequency tissue ablation: increased lesion diameter with a perfusion electrode. Acad Radiol 1996; 3: 636-44.
24. Pennes H. Analysis of tissue and arterial blood temperatures in the resting human forearm. J App Physiol 1948; 1: 93-122.
25. Lobo SM, Afzal SK, Ahmed M, Kruskal JB, Lenkinski RE, Goldberg SN. Radiofrequency ablation: modeling the enhanced temperature response to adjuvant NaC1 pretreatment. Radiology 2004 Jan; 230(1 : 175-82.
26. Ahmed M, Lobo SM, Weinstein J, Kruskal JB, Gazelle GS, Halpern EF, Afzal SK, Lenkinski RE, Goldberg SN. Improved coagulation with saline solution pretreatment during radiofrequency tumor ablation in a canine model. J Vasc Interv Radiol 2002; 13: 717-24.
27. Goldberg SN, Ahmed M, Gazelle GS, Kruskal JB, Huertas JC, Halpern EF, Oliver BS, Lenkinski RE. Radiofrequency thermal ablation with adjuvant saline injection: effect of electrical conductivity on tissue heating and coagulation. Radiology 2001; 219: 157-65.
28. Rossi S, Garbagnati F, Lencioni R, Allgaier HP, Marchiano A, Fornari F, Quaretti P, Tolla GD, Ambrosi C, Mazzaferro V, Blum HE, Bartolozzi C. Percutaneous radiofrequency thermal ablation of nonresectable hepatocellular carcinoma after occlusion of tumor blood supply. Radiology 2000; 217: 119-26.
29. Kainuma O, Asano T, Aoyama H, Takayama W, Nakagohri T, Kenmochi T, Hasegawa M, Tokoro Y, Sasagawa S, Ochiai T. Combined therapy with radiofrequency thermal ablation and intra-arterial infusion chemotherapy for hepatic metastases from colorectal cancer. Hepatogastroenterology 1999; 46: 1071-7.
30. Goldberg SN, Kruskal JB, Oliver BS, Clouse ME, Gazelle GS. Percutaneous tumor ablation: increased coagulation by combining radiofrequency ablation and ethanol instillation in a rat breast tumor model. Radiology 2000; 217: 827-31.
31. McGahan JP, Brock JN, Tessluk H, Wei-Zhong G, Schneider P, Browning PD. Hepatic ablation with use of RF electrocautery in the animal model. JVIR 1992; 3: 291-7.
32. Seegenschmiedt M, Brady L, Sauer R. Interstitial thermoradiotherapy: review on technical and clinical aspects. Am J Clin Oncol 1990; 13: 352-63.
33. Trembley B, Ryan T, Strohbehn J. Interstitial hyperthermia: physics, biology, and clinical aspects. Hyperthermia and Oncology, Vol 3. Utrecht: VSP, 1992; 11-98.
34. Christophi C, Winkworth A, Muralihdaran V, Evans P. The treatment of malignancy by hyperthermia. Surg Oncol 1998; 7: 83-90.
35. Kong G, Dewhirst MW. Hyperthermia and liposomes. Int J Hyperthermia 1999; 15: 345-70.
36. Huang SK, Stauffer PR, Hong K, Guo JW, Phillips TL, Huang A, Papahadjopoulos D. Liposomes and hyperthermia in mice: increased tumor uptake and therapeutic efficacy of doxorubicin in sterically stabilized liposomes. Cancer Res 1994; 54: 2186-91.
37. Cosman E, Nashold B, Ovelman-Levitt J. Theoretical aspects of radiofrequency lesions in the dorsal root entry zone. Neurosurgery 1984; 15: 945-50.
38. Organ LW. Electrophysiologic principles of radiofrequency lesion making. Appl Neurophysiol 1976; 39: 69-76.
39. Ryan TP, Goldberg SN. Comparison of simulation and experimental results for RF thermal treatment devices with or without cooling. Proc SPIE 1999; 3594: 14-25.
40. Nah BS, Choi IB, Oh WY, Osborn JL, Song CW. Vascular thermal adaptation in tumors and normal tissue in rats. Int J Radiat Oncol Biol Phys 1996; 35: 95-101.
41. Goldberg SN, Saldinger PF, Gazelle GS, Huertas JC, Stuart KE, Jacobs T, Kruskal JB. Percutaneous tumor ablation: increased coagulation necrosis with combined radiofrequency and percutaneous doxorubicin injection. Radiology 2001; 220: 420-7.
42. Goldberg SN, Girnan GD, Lukyanov AN, Ahmed M, Monsky WL, Gazelle GS, Huertas JC, Stuart KE, Jacobs T, Torchillin VP, Halpern EF, Kruskal JB. Percutaneous tumor ablation: increased necrosis with combined radio-frequency ablation and intravenous liposomal doxorubicin in a rat breast tumor model. Radiology 2002; 222: 797-804.
43. Monsky WL, Kruskal JB, Lukyanov AN, Girnun GD, Ahmed M, Gazelle GS, Huertas JC, Stuart KE, Torchilin VP, Goldberg SN. Radio-frequency ablation increases intratumoral liposomal doxorubicin accumulation in a rat breast tumor model. Radiology 2002; 224: 823-9.
44. Goldberg SN, Kamel IR, Kruskal JB, Reynolds K, Monsky WL, Stuart KE, Ahmed M, Raptopoulos V. Radiofrequency ablation of hepatic tumors: increased tumor destruction with adjuvant liposomal doxorubicin therapy. AJR Am J Roentgenol 2002; 179: 93-101.
45. D'Ippolito G, Ahmed M, Girnun GD, Stuart KE, Kruskal JB, Halpern EF, Goldberg SN. Percutaneous tumor ablation: increased endpoint survival with combined radiofrequency ablation and liposomal doxorubicin in a rat breast tumor model. Radiology 2003; 228: 112-8.
46. Ahmed M, Monsky WE, Girnun G, Lukyanov A, D'Ippolito G, Kruskal JB, Stuart KE, Torchilin VP, Goldberg SN. Radiofrequency thermal ablation sharply increases intratumoral liposomal doxorubicin accumulation and tumor coagulation. Cancer Res 2003; 63: 6327-33.
47. Livraghi T, Giorgio A, Marin A. Hepatocellular carcinoma and cirrhosis in 746 patients: long-term results of percutaneous ethanol injection. Radiology 1995; 197: 101-8.
48. Shiina S, Tagawa K, Niwa Y. Percutaneous ethanol injection therapy for hepatocellular carcinoma: results in 146 patients. AJR Am J Roentgenol 1993; 160: 1023-5.
49. Alexander DG, Unger EC, Seeger SJ, Karmann S, Krupinski EA. Estimation of volumes of distribution and intratumoral ethanol concentrations by computed tomography scanning after percutaneous ethanol injection. Acad Radiol 1996; 3: 49-56.
50. Sanz-Altamira PM, Spence LD, Huberman MS, Posner MR, Steel G Jr, Perry LJ, Stuart KE. Selective chemoembolization in the management of hepatic metastases in refractory colorectal carcinoma: a phase II trial. Dis Colon Rectum 1997; 40: 770-5.
51. Chung JW, Park JH, Han JK, Choi BI, Han MC. Hepatocellular carcinoma and portal vein invasion: results of treatment with transcatheter oily chemoembolization. AJR Am J Roentgenol 1995; 165: 315-21.
52. Kemeny N, Huang Y, Cohen AM, Shi W, Conti JA, Brennan MF, Bertino JR, Turnbull AD, Sullivan D, Stockman J, Blumgart LH, Fong Y. Hepatic arterial infusion of chemotherapy after resection of hepatic metastases from colorectal cancer. N Engl J Med 1999; 341: 2039-48.
53. Kong G, Braun RD, Dewhirst MW. Characterization of the effect of hyperthermia on nanoparticle extravasation from tumor vasculature. Cancer Res 2001; 61: 3027-32.
54. Gregoriadis G. Liposomes as drug carriers. New York: Wiley, 1988.
55. Lasic D, Martin F. Stealth liposomes. Boca Raton, FL: CRC Press, 1995.
56. Torchilin VP, Klibanov AL, Huang L, O'Donnell S, Nossiff ND, Khaw BA. Targeted accumulation of polyethylene glycol-coated immunoliposomes in infarcted rabbit myocardium. Faseb J 1992; 6: 2716-9.
57. Senior JH. Fate and behavior of liposomes in vivo: a review of controlling factors. Crit Rev Ther Drug Carrier Syst 1987; 3: 123-93.
58. Gabizon AA. Selective tumor localization and improved therapeutic index of anthracyclines encapsulated in long-circulating liposomes. Cancer Res 1992; 52: 891-6.
59. Klibanov AL, Maruyama K, Torchilin VP, Huang L. Amphipathic polyethyleneglycols effectively prolong the circulation time of liposomes. FEBS Lett 1990; 268: 235-7.
60. Torchilin VP. Liposomes as targetable drug carriers. Crit Rev Ther Drug Carrier Syst 1985; 2: 65-115.
61. Vaage J, Barbara E. Tissue uptake and therapeutic effects of stealth doxorubicin. In: Lasic D, Martin F, eds, Stealth Liposomes. Boca Raton, FL: CRC Press, 1995; pp. 149-72.
62. Gabizon A, Shiota R, Papahadjopoulos D. Pharmacokinetics and tissue distribution of doxorubicin encapsulated in stable liposomes with long circulation times. J Natl Cancer Inst 1989; 81: 1484-8.
63. Ranson MR, Carmichael J, O'Byrne K, Stewart S, Smith D, Howell A. Treatment of advanced breast cancer with sterically stabilized liposomal doxorubicin: results of a multicenter phase II trial. J Clin Oncol 1997; 15: 3185-91.
64. Gordon AN, Granai CO, Rose PG, Hainsworth J, Lopez A, Weissman C, Rosales R, Sharpington T. Phase II study of liposomal doxorubicin in platinum- and paclitaxel-refractory epithelial ovarian cancer. J Clin Oncol 2000; 18: 3093-100.
65. Rivera E, Valero V, Arun B, Royce M, Adinin R, Hoelzer K, Walters R, Wade JL 3rd, Pusztai L, Hortobagyi GN. Phase II study of pegylated liposomal doxorubicin in combination with gemcitabine in patients with metastatic breast cancer. J Clin Oncol 2003; 21: 3249-54.
66. Ruff P, Moodley SD, Rapoport BL, Vorobiof DA, Maart K, Chasen MR. Long term follow-up of pegylated liposomal doxorubicin (Caelyx): a well tolerated and effective agent in advanced hepatocellular carcinoma (HCC). ASCO Annual Meeting 2001; Abstract: 667.
67. Mayhew EG, Goldrosen MH, Vaage J, Rustum YM. Effects of liposome-entrapped doxorubicin on liver metastases of mouse colon carcinomas 26 and 38. J Natl Cancer Inst 1987; 78: 707-13.
68. Storm G, Roerdink FH, Steerenberg PA, de Jong WH, Crommelin DJ. Influence of lipid composition on the antitumor activity activity exerted by doxorubicin-containing liposomes in a rat solid tumor model. Cancer Res 1987; 47: 3362-72.
69. Ning S, Macleod K, Abra RM, Huang AH, Hahn GM. Hyperthermia induces doxorubicin release from long-circulating liposomes and enhances their anti-tumor efficacy. Int J Radiat Oncol Biol Phys 1994; 29: 827-34.
70. van Bree C, Krooshoop JJ, Rietbroek RC, Kipp JB, Bakker PJ. Hyperthermia enhances tumor uptake and antitumor efficacy of thermostable liposomal daunorubicin in a rat solid tumor model. Cancer Res 1996; 56: 563-8.
71. Kong G, Anyarambhatla G, Petros WP, Braun RD, Colvin OM, Needham D, Dewhirst MW. Efficacy of liposomes and hyperthermia in a human tumor xenograft model: importance of triggered drug release. Cancer Res 2000; 60: 6950-7.
72. Needham D, Anyarambhatla G, Kong G, Dewhirst MW. A new temperature-sensitive liposome for use with mild hyperthermia: characterization and testing in a human tumor xenograft model. Cancer Res 2000; 60: 1197-201.
73. Zou Y, Yamagishi M, Horikoshi I, Ueno M, Gu X, Perez-Soler R. Enhanced therapeutic effect against liver W256 carcinosarcoma with temperature-sensitive liposomal adriamycin administered into the hepatic artery. Cancer Res 1993; 53: 3046-51.
74. Gabizon A, Catane R, Uziely B, Kaufman B, Safra T, Cohen R, Martin F, Huang A, Barenholz Y. Prolonged circulation time and enhanced accumulation in malignant exudates of doxorubicin encapsulated in polyethylene-glycol coated liposomes. Cancer Res 1994; 54: 987-92.
75. Ahmed M, Horkan C, Liu Z, Lukyanov AN, Torchilin VP, Goldberg SN. Combined radiofrequency ablation with liposomal doxorubicin increases doxorubicin uptake and coagulation in normal rabbit and rat tissues. Radiology 2003; 229: 410.
76. Ahmed M, Liu Z, Horkan C, Torchilin VP, Lukyanov AN, Goldberg SN. Radiofrequency tumor ablation combined with intravenous liposomal doxorubicin increases tumor coagulation and intratumoral drug accumulation in a large animal tumor model. Radiology 2003; 229: 457.
77. Gnant MF, Noll LA, Terrill RE, Wu PC, Berger AC, Nguyen HQ, Lans TE, Flynn BM, Libutti SK, Bartlett DL, Alexander HR Jr. Isolated hepatic perfusion for lapine liver metastases: impact of hyperthermia of permeability of tumor neovasculature. Surgery 1999; 126: 890-9.
78. Dudar TE, Jain RK. Differential response of normal and tumor microcirculation to hyperthermia. Cancer Res 1984; 44: 605-12.
79. Yuan F, Dellian M, Fukumura D, Leunig M, Berk DA, Torchilin VP, Jain RK. Vascular permeability in a human tumor xenograft: molecular size dependence and cutoff size. Cancer Res 1995; 55: 3752-6.
80. Hobbs SK, Monsky WL, Yuan F, Roberts WG, Griffith L, Torchilin VP, Jain RK. Regulation of transport pathways in tumor vessels: role of tumor type and microenvironment. Proc Natl Acad Sci USA 1998; 95: 4607-12.
81. Monsky WL, Fukumura D, Gohongi T, Ancukiewcz M, Weich HA, Torchilin VP, Yuan F, Jain RK. Augmentation of transvascular transport of macromolecules and nanoparticles in tumors using vascular endothelial growth factor. Cancer Res 1999; 59: 4129-35.
82. Kong G, Braun RD, Dewhirst MW. Hyperthermia enables tumor-specific nanoparticle delivery: effect of particle size. Cancer Res 2000; 60: 4440-5.
83. Kruskal JB, Oliver B, Huertas JC, Goldberg SN. Dynamic intrahepatic flow and cellular alterations during radiofrequency ablation of liver tumors in mice. JVIR 2001; 12: 1193-201.
84. Nishita T. Heat-sensitive liposomes containing cisplatin and localized hyperthermia in treatment of murine tumor. Osaka City Med J 1998; 44: 73-83.
85. Toffoli G, Bevilacqua C, Franceschin A, Boiocchi M. Effect of hyperthermia on intracellular drug accumulation and chemosensitivity in drug-sensitive and drug-resistant P388 leukaemia cell lines. Int J Hyperthermia 1989; 5: 163-72.
86. Merlin JL, Marchal S, Ramacci C, Notter D, Vigneron C. Reversal of multidrug resistance by thermosensitive liposome-encapsulated doxorubicin combined with hyperthermia. Proc Ann Meet Am Assoc Cancer Res 1993; 34: A1901.
87. Kawai H, Minamiya Y, Kitamura M, Matsuzaki I, Hashimoto M, Suzuki H, Abo S. Direct measurement of doxorubicin concentration in the intact, living single cancer cell during hyperthermia. Cancer 1997; 79: 214-9.
88. Osborne EJ, MacKillop WJ. The effect of exposure to elevated temperatures on membrane permeability to adriamycin in Chinese hamster ovary cells in vitro. Cancer Lett 1987; 37: 213-24.
89. Kruskal JB, Hlatky L, Hahnfeldt P, Teramoto K, Stokes KR, Clouse ME. in vivo and in vitro analysis of the effectiveness of doxorubicin combined with temporary arterial occlusion in liver tumors. J Vasc Interv Radiol 1993; 4: 741-7.
90. Spector AA, Burns CP. Biological and therapeutic potential of membrane lipid modification in tumors. Cancer Res 1987; 47: 4529-37.
91. Yoshikawa T, Kokura S, Tainaka K, Itani K, Oyamada H, Kaneko T, Naito Y, Kondo M. The role of active oxygen species and lipid peroxidation in the antitumor effect of hyperthermia. Cancer Res 1993; 53: 2326-9.
92. Kokura S, Yoshikawa T, Kaneko T, Iinuma S, Nishimura S, Matsuyama K, Naito Y, Yoshida N, Kondo M. Efficacy of hyperthermia and polyunsaturated fatty acids on experimental carcinoma. Cancer Res 1997; 57: 2200-2.
93. Kinter M, Spitz DR, Roberts RJ. Oleic acid incorporation protects cultured hamster fibroblasts from oxygen-induced cytotoxicity. J Nutr 1996; 126: 2952-9.
94. Working PK, Dayan AD. Pharmacological-toxicological expert report. CAELYX (Stealth liposomal doxorubicin HCl). Hum Exp Toxicol 1996; 15: 751-85.
95. Wells J, Sen A, Hui SW. Localized delivery to CT-26 tumors in mice using thermosensitive liposomes. Int J Pharm 2003; 261: 105-14.
96. Shimose S, Sugita T, Nitta Y, Kubo T, Ikuta Y, Murakami T. Effect of thermosensitive liposomal doxorubicin with hyperthermia on primary tumor and lung metastases in hamster osteosarcoma. Int J Oncol 2001; 19: 585-9.
97. Park JW, Hong K, Kirpotin DB, Colbern G, Shalaby R, Baselga J, Shao Y, Nielsen UB, Marks JD, Moore D, Papahadjopoulos D, Benz CC. Anti-HER2 immunoliposomes: enhanced efficacy attributable to targeted delivery. Clin Cancer Res 2002; 8: 1172-81.